279 related articles for article (PubMed ID: 22168776)
41. Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
Zeuzem S; Yoshida EM; Benhamou Y; Pianko S; Bain VG; Shouval D; Flisiak R; Rehak V; Grigorescu M; Kaita K; Cronin PW; Pulkstenis E; Subramanian GM; McHutchison JG
Hepatology; 2008 Aug; 48(2):407-17. PubMed ID: 18666223
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of pegylated interferon and ribavirin for retreatment of chronic HCV infection in HIV co-infected patients failing a previous standard interferon-based regimen.
Crespo M; Mira JA; Pineda JA; Van den Eynde E; Ríos-Villegas MJ; Collado A; Girón-González JA; López-Cortés LF; González-Serrano M; Rivero A; Merino D; Esteban JI
J Antimicrob Chemother; 2008 Oct; 62(4):793-6. PubMed ID: 18567911
[TBL] [Abstract][Full Text] [Related]
43. Treatment of eosinophilic otitis media with pegylated interferon-α 2a and 2b.
Neff BA; Voss SG; Carlson ML; O'Brien EK; Butterfield JH
Laryngoscope; 2017 May; 127(5):1208-1216. PubMed ID: 27667784
[TBL] [Abstract][Full Text] [Related]
44. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
45. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
Geskin L
Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
[TBL] [Abstract][Full Text] [Related]
46. A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.
Coker SA; Dandamudi UB; Beelen AP; Crosby NA; Fisher JL; Obrocea M; Ernstoff MS; Lewis LD
J Chemother; 2013 Dec; 25(6):362-8. PubMed ID: 24093213
[TBL] [Abstract][Full Text] [Related]
47. Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients.
Fumaz CR; Muñoz-Moreno JA; Ballesteros AL; Paredes R; Ferrer MJ; Salas A; Fuster D; Masmitjà E; Pérez-Alvarez N; Gómez G; Tural C; Clotet B
AIDS Care; 2007 Jan; 19(1):138-45. PubMed ID: 17129869
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.
Reddy KR; Wright TL; Pockros PJ; Shiffman M; Everson G; Reindollar R; Fried MW; Purdum PP; Jensen D; Smith C; Lee WM; Boyer TD; Lin A; Pedder S; DePamphilis J
Hepatology; 2001 Feb; 33(2):433-8. PubMed ID: 11172346
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
51. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
52. [Pegylated interferon alpha 2a in treating chronic hepatitis B patients].
Tian YL; Zhao W; Shen L; Liu W; Chang JB; Fang ZX; Yin WW; Wang L; Sun XB; Yang YJ
Zhonghua Gan Zang Bing Za Zhi; 2006 Nov; 14(11):806-10. PubMed ID: 17125604
[TBL] [Abstract][Full Text] [Related]
53. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
54. Narrow band UVB (311 nm), psoralen UVB (311 nm) and PUVA therapy in the treatment of early-stage mycosis fungoides: a right-left comparative study.
El-Mofty M; El-Darouty M; Salonas M; Bosseila M; Sobeih S; Leheta T; Nada H; Tawdy A; Amin I; El-Enany G
Photodermatol Photoimmunol Photomed; 2005 Dec; 21(6):281-6. PubMed ID: 16313238
[TBL] [Abstract][Full Text] [Related]
55. Primary cutaneous T cell lymphomas: photochemotherapy immunomodulation with analysis of the inflammatory-expansive cellular dynamic.
Werber-Bandeira L; Herdy AM; Pagani EA; Filgueira AL
Dermatol Ther; 2014; 27(2):74-8. PubMed ID: 24703262
[TBL] [Abstract][Full Text] [Related]
56. Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients.
Ali S; Nazir G; Khan SA; Iram S; Fatima F
J Ayub Med Coll Abbottabad; 2010; 22(4):127-30. PubMed ID: 22455279
[TBL] [Abstract][Full Text] [Related]
57. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K; Kaufmann R; Dummer R; Garbe C; Becker JC; Hauschild A; Tilgen W; Ugurel S; Beyeler M; Bröcker EB; Kaehler KC; Pföhler C; Gille J; Leiter U; Schadendorf D
Ann Oncol; 2008 Apr; 19(4):801-6. PubMed ID: 18178958
[TBL] [Abstract][Full Text] [Related]
58. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
Dummer R; Garbe C; Thompson JA; Eggermont AM; Yoo K; Maier T; Bergstrom B
J Clin Oncol; 2006 Mar; 24(7):1188-94. PubMed ID: 16505439
[TBL] [Abstract][Full Text] [Related]
59. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
[TBL] [Abstract][Full Text] [Related]
60. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
